VTVT | tickerfilter.com

Fundamental analysis

23%

Profitability 30%

Dept financing 25%

Liquidity 20%

Performance 17%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-19.01%

1 Month

-14.93%

3 Months

-3.68%

6 Months

54.60%

1 Year

41.39%

2 Year

16.25%

Key data

Stock price

$32.76

P/E Ratio

0.00

DAY RANGE

$32.00 - $35.01

EPS

-$3.40

52 WEEK RANGE

$14.00 - $44.00

52 WEEK CHANGE

$41.39

MARKET CAP

74.593 M

YIELD

N/A

SHARES OUTSTANDING

3.938 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.37

PUBLIC FLOAT

AVERAGE 10 VOLUME

$78,530

AVERAGE 30 VOLUME

$59,143

Company detail

CEO: Paul J. Sekhri
Region: US
Website: vtvtherapeutics.com
Employees: 9
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

vTv Therapeutics focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion.

VTVT - vTv Therapeutics Inc.